Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. M. Dorinsky, S. W. Yancey, B. A. Prillaman, L. B. Sutton, J. L. Stauffer (Research Triangle Park, United States Of America). Retrospective review of studies shows that patients receiving salmeterol plus ICS have fewer serious asthma exacerbations vs patients on ICS alone, regardless of ethnic origin. Eur Respir J 2005; 26: Suppl. 49, 2767

Member's Comments

No comment yet.

Related content which might interest you: Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Factors influencing LAMA addition to COPD patients receiving ICS/LABA in clinical practice-RETRIEVE study. Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Is the combination of long-acting β2-agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma? Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005 Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Unlicensed use of high-dose inhaled corticosteroids in the UK occurs principally with fluticasone - an observational study of 26359 patients Source: Eur Respir J 2004; 24: Suppl. 48, 501s Year: 2004 Incidence of asthma-related hospitalizations with the addition of salmeterol to an ICS in subjects with asthma: a meta-analysis Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007 Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005